ICER: Antibodies For MS – Including TG’s – Need Big Price Cut For Cost-Effectiveness
Executive Summary
The pricing watchdog said it found “insufficient evidence” to differentiate the benefit of TG’s ublituximab from other antibodies already on the market for multiple sclerosis.
You may also be interested in...
MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space
The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.
TG Shifts Focus To MS After Pausing Oncology Programs, Ukoniq Withdrawal
TG Therapeutics is withdrawing the PI3K-delta inhibitor from the market and halting enrolling in other umbralisib oncology studies to focus attention on ublituximab in relapsing multiple sclerosis.
AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.